Inclusion Criteria:
- Participants ≥ 18 years of age with R/R NHL (including DLBCL [ie, DLBCL not otherwise
specified (NOS) and diffuse large B-Cell lymphoma/high-grade B-Cell lymphoma with MYC
and BCL2 rearrangements], and FL):
- For R/R DLBCL (de novo) and FL 3b: following at least 2 prior lines of therapy
(eg, first-line combination chemotherapy regimen containing rituximab,
anthracycline, an alkylating agent, and steroids and at least one additional
treatment).
- For R/R DLBCL (transformed lymphoma): following at least 2 prior lines of therapy
which must have been administered after transformation.
- For R/R FL (except for FL 3b): following at least 2 prior lines of therapy and
meeting treatment criteria at the time of enrollment based on investigator´s
assessment.
- Participant must have measurable disease (defined by at least one FDG-avid lesion for
FDG-avid disease and one bi-dimensionally measurable disease on cross sectional
imaging by computed tomography or magnetic resonance imaging with at least one lesion
> 1.5 cm in the transverse diameter).
- Participants must accept and follow pregnancy prevention plan.
Exclusion Criteria:
- Participants must not have an Eastern Cooperative Oncology Group (ECOG)22 performance
status ≥ 3.
- Participants with an inability to comply with listed restrictions, precautions and
prohibited treatments.
- Participants must not have prior CAR-T, Cereblon-modulating drug or radiotherapy ≤ 4
weeks, systemic anticancer treatment ≤ 5 half-lives or 4 weeks, allogeneic SCT ≤ 6
months or autologous SCT ≤ 3 months prior to study intervention initiation.
- Participants must not have any condition, including significant acute or chronic
medical illness, active or uncontrolled infection, or the presence of laboratory
abnormalities, that places participants at unacceptable risk if participating in this
study.
- Participants must not have known or suspected central nervous system involvement.
Recruiting
